1033538-21-4

Basic information

• Product Name: Cyclobutanecarbonyl chloride, 1-(trifluoroMethyl)-
• Synonyms: Cyclobutanecarbonyl chloride, 1-(trifluoroMethyl)-
• CAS NO: 1033538-21-4
• Molecular Formula: C₆H₆ClF₃O
• Molecular Weight: 186.5594496
• Mol File: 1033538-21-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 130.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.450±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Cyclobutanecarbonyl chloride, 1-(trifluoroMethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclobutanecarbonyl chloride, 1-(trifluoroMethyl)-(1033538-21-4)
• EPA Substance Registry System: Cyclobutanecarbonyl chloride, 1-(trifluoroMethyl)-(1033538-21-4)

Safety Data

• Hazardous Substances Data: 1033538-21-4(Hazardous Substances Data)

Upstream product

• 277756-45-3 (1-trifluoromethyl)cyclobutanecarboxylic acid 

Downstream Products

• 1021939-66-1 N,N-dimethyl-2-[2-(4-pyridin-2-ylphenyl)ethyl]-4-{[1-(trifluoromethyl)cyclobutyl]carbonyl}-1H-imidazole-1-sulfonamide 
• 1354043-34-7 C₂₃H₁₉F₄N₇O₂ 

Relevant articles and documents

FERROPTOSIS INHIBITORS–DIARYLAMINE PARA-ACETAMIDES

Provided are compounds that inhibit ferroptosis activity, or modulate or inhibit a disease associated with ferroptosis dysregulation, such as neuropathy, ischemia reperfusion injury, acute kidney failure and cancer, including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

SGC STIMULATORS

Compounds of Formula (I) are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.

Organic Compounds

The present invention relates to compounds of formula I and its salts, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.